Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 19/20 | 0.45 |
| ▸ | CASP6 | P55212 | 19/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 19/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421626 | 0.86 | CYP2D6 (0.37) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL627300 | 0.86 | CYP2D6 (0.37) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL627299 | 0.86 | CYP2D6 (0.37) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23268871 | 0.78 | CYP2D6 (0.36) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL4424248 | 0.78 | CYP2D6 (0.36) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL3893701 | 0.77 | MAPT (0.39) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL7202811 | 0.76 | CASP3 (0.54) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL10074260 | 0.76 | CASP3 (0.61) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL5795425 | 0.74 | CASP1 (0.43) | CASP3CASP6CASP8 | |
| SCHEMBL26623362 | 0.74 | CASP1 (0.43) | CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012021800-A2 | CASPASE INHIBITORS AS THERAPEUTICS FOR NEURAL AND ORGAN INJURY AND IMAGING | BANYAN BIOMARKERS (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6489353-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISORDERS | IDUN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-1159291-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6184244-B1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2001000658-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | CASP3 1/4885CASP6 37/4885CASP8 60/4885 |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | CASP3 1/4885CASP6 37/4885CASP8 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.